Drugs / RLD2209-2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06174766 Comparator | May 2024 → Jan 2026 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLD2209-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06174766 ↗ |
| Route | Oral | “take RLD2209-2 once daily for 6 weeks orally” NCT06174766 ↗ |